IDEC-C2B8 chimeric anti-CD20 antibody (MAB): Safety and clinical activity in the treatment of patients (PTS) with relapsed low-grade or follicular (IWF:A-D) non-Hodgkin's lymphoma (NHL)

被引：0
|
作者：
GrilloLopez, AJ [1 ]
Varns, C [1 ]
Waldichuk, C [1 ]
Dallaire, BK [1 ]
Rosenberg, J [1 ]
McClure, A [1 ]
Shen, D [1 ]
机构：
[1] IDEC PHARMACEUT CORP,SAN DIEGO,CA
来源：
BRITISH JOURNAL OF HAEMATOLOGY | 1996年 / 93卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1072 / 1072
页数：1
相关论文
共 50 条
  • [41] Chimeric anti-CD20 monoclonal antibody (Mabthera) in remission induction and maintenance treatment of relapsed follicular non-Hodgkin's lymphoma: a phase III randomized clinical trial – Intergroup Collaborative Study
    M. van Oers
    A. Hagenbeek
    M. Van Glabbeke
    I. Teodorovic
    Annals of Hematology, 2002, 81 : 553 - 557
  • [42] Clinical trials of a mouse-human chimeric anti-CD20 monoclonal antibody (rituximab) for B cell non-Hodgkin's lymphoma in Japan
    Tobinai, K
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2001, 48 (Suppl 1) : S85 - S90
  • [43] Clinical trials of a mouse-human chimeric anti-CD20 monoclonal antibody (rituximab) for B cell non-Hodgkin's lymphoma in Japan
    Kensei Tobinai
    Cancer Chemotherapy and Pharmacology, 2001, 48 : S85 - S90
  • [44] Chimeric anti-CD20 monoclonal antibody (Rituximab; Mabtheraa) in remission induction and maintenance treatment of relapsed/resistant follicular non-Hodgkin's lymphoma: A phase III randomized intergroup clinical trial.
    Van Oers, MHJ
    Van Glabbeke, M
    Teodorovic, L
    Rozewicz, C
    Klasa, R
    Marcus, RE
    Wolf, M
    Kimby, E
    Hagenbeek, A
    BLOOD, 2004, 104 (11) : 169A - 169A
  • [45] Clinical experience with Iodine-131 Anti-B1 antibody for the treatment of low-grade and transformed low-grade non-Hodgkin's lymphoma
    Bhatnagar, A
    Kroll, S
    Langmuir, V
    Tidmarsh, G
    Wahl, R
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE, 1999, 26 (09): : 970 - 970
  • [46] Clinical Activity of REGN1979, a Bispecific Human, Anti-CD20 x Anti-CD3 Antibody, in Patients with Relapsed/Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (B-NHL)
    Bannerji, Rajat
    Allan, John N.
    Arnason, Jon E.
    Brown, Jennifer R.
    Advani, Ranjana H.
    Barnes, Jeffrey A.
    Ansell, Stephen M.
    O'Brien, Susan M.
    Chavez, Julio
    Duell, Johannes
    David, Kevin A.
    Martin, Peter
    Joyce, Robin M.
    Charnas, Robert
    Ambati, Srikanth R.
    Adriaens, Lieve
    Ufkin, Melanie
    Zhu, Min
    Li, Jingjin
    Gasparini, Peter
    Ibrahim, Anfal
    Jankovic, Vladimir
    Fiaschi, Nathalie
    Aina, Olulanu
    Zhang, Wen
    Deering, Raquel P.
    Hamon, Sara
    Thurston, Gavin
    Murphy, Andrew J.
    Weinreich, David M.
    Yancopoulos, George D.
    Lowy, Israel
    Sternberg, David
    Topp, Max S.
    BLOOD, 2019, 134
  • [47] A multicenter phase II study of iodine-131 anti-B1 antibody (Bexxar) in patients (pts) with chemotherapy-relapsed/refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphoma (NHL)
    Kaminski, MS
    Vose, J
    Saleh, M
    Lister, A
    Knox, S
    Crowther, D
    Zelenetz, AD
    Colcher, D
    Wahl, R
    BLOOD, 1997, 90 (10) : 2268 - 2268
  • [48] Efficacy and safety of monoclonal anti-CD20 antibody (rituximab) for the treatment of patients with recurrent low-grade non-Hodgkin's lymphoma after high-dose chemotherapy and autologous hematopoietic cell transplantation
    Kaya, H
    Keung, YK
    Case, D
    Cruz, JM
    Perry, JJ
    Radford, JE
    Hurd, DD
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2002, 8 (10) : 544 - 549
  • [49] Chimeric anti-CD20 monoclonal antibody (rituximab; mabthera) in remission induction and maintenance treatment of relapsed/resistant follicular non-Hodgkin's lymphoma: Final analysis of a phase III randomized intergroup clinical trial
    Van Oers, M. H. J.
    Van Glabbeke, M.
    Teodorovic, I.
    Rozewicz, C.
    Klasa, R.
    Marcus, R. E.
    Wolf, M.
    Kimby, E.
    Hagenbeek, A.
    Kersten, M. J.
    ANNALS OF HEMATOLOGY, 2006, 85 : 47 - 47
  • [50] PHASE-I CLINICAL-TRIAL USING ESCALATING SINGLE-DOSE INFUSION OF CHIMERIC ANTI-CD20 MONOCLONAL-ANTIBODY (IDEC-C2B8) IN PATIENTS WITH RECURRENT B-CELL LYMPHOMA
    MALONEY, DG
    LILES, TM
    CZERWINSKI, DK
    WALDICHUK, C
    ROSENBERG, J
    GRILLOLOPEZ, A
    LEVY, R
    BLOOD, 1994, 84 (08) : 2457 - 2466
12345